CLOSE

Dialog Box

Loading...
NET Patient Symposium 2018

Nov 11, 2018 at 1:00PM

NET Patient Symposium 2018

Join us for our NET Patient Symposium following on from APNETS in Melbourne. We are very excited that our program includes a range of world leading NET experts. Registration is now open.
   
When
Nov 11, 2018 at 1:00PM
Nov 11, 2018 at 5:00PM
(UTC+10:00) Canberra, Melbourne, Sydney
Registrations Close
Nov 5, 2018 at 12:00AM
Venue
MCEC Melbourne Convention and Exhibition and Centre
(Room TBC)
Location
1 Convention Centre Pl
South Wharf
Melbourne, VIC, 3006
Contact:
Simone Leyden
0419871975
General Notes:
Type
Price
Notes
Registration
$0.00
Book Now
The Unicorn Foundation NET Patient Symposium will be held on Sunday November 11th and we extend a warm welcome to anyone with an interest in NETs including patients, carers, family members and health professionals

We are excited to announce our program for the day will includes leaders in NETs from Australia, New Zealand and around the world. Please click here for full copy of program.

Afternoon tea will be provided (please indicate any dietary preferences when booking or email Linda Ryding)

Registration is required for catering so book now to avoid missing out!

Guest speakers include:

Dr James Yao 
James Yao, MD, is professor and chairman of gastrointestinal medical oncology at the MD Anderson Cancer Center, Houston, Texas, United States. He was the chair emeritus of the North American Neuroendocrine Tumor Society (NANETS). He has numerous awards including the American Society of Clinical Oncology Career Development Award 2003, and the Carcinoid Cancer Foundation Research Award 2006, MD Anderson Distinguished Alumni Award 2009, Irwin H. Krakoff Excellence in Clinical Research Award 2011, and The Murray Brennan Distinguished Lecturer, Memorial Sloan-Kettering Cancer Center, 2012.

In 1995, Dr. Yao received his doctorate of medicine at Baylor College of Medicine, Houston, Texas, United States. His credentials include board of certification in internal medicine (ABIM) in 1999 and board of certification in medical oncology (ABIM) in 2003.

Dr. Yao has special interests in neuroendocrine tumors and gastric cancer and has authored over 100 manuscripts including practice-changing articles in New England Journal of Medicine and Lancet. He has also been a principal investigator in numerous investigator initiated and multicenter clinical studies. He led the development of everolimus in neuroendocrine tumors from first patient treated through FDA approval for pancreatic neuroendocrine tumors in 2011 and lung and gastrointestinal neuroendocrine tumors in 2016.

Dr Simona Glasberg 
Head of the Neuroendocrine Tumor Unit & Senior Lecturer in Endocrinology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

A specialist in endocrinology and internal medicine, Dr. Glasberg completed a fellowship in Neuroendocrinology at St. Bartholomew's Hospital & William Harvey Research Institute, London, UK, exploring the mechanisms by which somatostatin analogues regulate the growth of NETs, and their interaction with mTOR inhibitors. Established as one of the foremost experts in the diagnosis and management of NETs in Israel, Dr. Glasberg is actively involved in both, the care of patients with NETs, as well as in the research in the field. Dr. Glasberg is a member of the Advisory Board of the European Neuroendocrine Tumor Society (ENETS). She has published extensively in peer-reviewed journals, and presented at national and international conferences on the topic of NETs. Dr. Glasberg is the recipient of the prestigious 2017 Lindner Prize of the Israel Endocrine Society, in recognition for her scientific achievements and contribution in the field of NETs.

Dr Ben Lawrence 
Dr Lawrence is an Auckland-trained Medical Oncologist who specializes in gastrointestinal cancers and neuroendocrine tumours. He previously completed a two year research Fellowship at Yale University studying the molecular biology of Neuroendocrine tumours, with a focus on developing alternative biomarkers related to tumour proliferation. He was previously a Drug Development Scholar at TGen in Scottsdale Arizona. He returned to Auckland in August 2012 and established a nationwide translational project involving tumour collection (clinically annotated retrospective and prospective) and developed a virtual multi-centre tumour board for Neuroendocrine Tumours. Working with Professor Cris Print as a translational partner, they undertake multi-level genomic profiling of NETs to create predictive models based in the genomic constituents of each tumour.


Prof Rodney Hicks
Rod is a Professor of Medicine and Radiology at the University of Melbourne and Director of the Centre for Cancer Imaging at the Peter MacCallum Cancer Centre in Melbourne, Australia. Peter Mac installed the first PET/CT outside Europe and North America in 2001 and now has an experience of over 75,000 PET studies performed in the facility founded by him in 1996. He received a prestigious National Health and Medical Research Council Program Grant in 2013 and an NHMRC Practitioner Fellowship in 2015. He was also induced as a Fellow of the Australian Academy of Health and Medical Science in 2015.


A/Prof Michael Michael 
Assoc. Prof Michael is a Gastrointestinal and Neuroendocrine Medical Oncologist, with a significant major track record in academic oncology with considerable expertise in clinical/translational trials and their design. His Medical Oncology training was attained at the Peter MacCallum Cancer Centre, he was a Clinical Fellow to the Department of Medicine at the Princess Margaret Hospital/Ontario Cancer Institute in Toronto, Canada, pursuing his research in gastrointestinal oncology. He was awarded the degree of Doctorate of Medicine (Monash University) in 2009. Assoc. Prof Michael has been the Principal Investigator (institutional/national) and the principal designer/co-designer for several oncology trials. He has significant research interests/expertise in combined modality therapies for GI malignancies including NETs and supervising post-graduate PhD students in translational and clinical studies both in GI and NET oncology.

He co-chairs the PeterMac Neuroendocrine Unit- with a national/international referral base and helped establish the first national NET Clinic at his institution and the development of post-graduate training courses in this area. The Neuroendocrine Unit is currently applying for European Neuroendocrine Tumour Society Centre of Excellence- the first such centre to be located outside Europe.

His research work has generated over 7 million dollars in competitive grant funding and 4 million dollars from industry. He has over 130 publications including high impact peer-reviewed articles, book chapters and reviews, with multiple presentations at local/international conferences and has authored/co-authored over 120 conference abstracts. He has given over 75 invited presentations in local/international forums. Assoc Prof Michael has been a reviewer for numerous international oncology journals and external reviewer for several local and international oncology funding bodies.

Prof Halfdan Sorbye 
Professor and Head of NET and GI section at Department of Oncology, Haukeland University Hospital, Bergen, Norway. He has a major research focus on Gastroenteropancreatic (GEP) Neuroendocrine carcinoma (NEC), Neuroendocrine Tumors (NET) and metastatic colorectal cancer and also 100 peer review publications, 3330 citations. The landmark study Nordic NEC in 2013 showed for the first time that the GEP WHO G3 group was a very heterogeneous group both concerning prognosis and with regard to response to chemotherapy. He is also a member of the ENETS advisory board, a faculty member for Endocrine Tumors and Gastro-Intestinal Tumors for ESMO (European Society of Medical Oncology) and executive Board for Nordic Neuroendocrine Tumor Group.

His most relevant publications:

The NORDIC NEC study. Ann Oncol 2013, 24: 152-160. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer 2014, 120: 2814-23, High-grade gastroenteropancreatic neuroendocrine carcinoma. UpToDate, 2018, Unmet needs in high-grade GEP neuroendocrine neoplasms (WHO G3). Neuroendocrinology 2018.

Dr Erin Kennedy
Erin is an accredited practicing dietitian with an interest in the nutritional assessment and management of patients with neuroendocrine tumours. She has worked as a clinical dietitian for 10 years, and specialised in the nutritional management of patients diagnosed with upper gastrointestinal cancer and NETs. Erin is working as a senior dietitian within the NET and Upper Gastrointestinal Unit at Peter MacCallum Cancer Centre in Melbourne, and regularly manages patients attending the multidisciplinary NET clinic. She has experience in teaching and clinical research, and is currently completing her PhD at the University of Melbourne, researching the topic of nutritional complications and quality of life amongst patients with gastroenteropancreatic neuroendocrine tumours. In addition to her work Erin has assisted with nutrition education sessions for local and interstate NET patient support groups, and recently collaborated with the Unicorn Foundation to create an evidence-based educational booklet for NET patients titled ‘Nutrition and NETs’.

Other speakers include:
Prof Dermot O'Toole
Dr Grace Kong
Alex Murray

Speakers from Unicorn Foundation:
Simone Leyden, Co-founder and CEO
Kate Wakelin, NET Nurse
Meredith Cummins, Project Officer NSW





Contact Us for Further Information

Name: Simone Leyden
Phone: 0419871975
Category: Research
Tags: